The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: a cluster randomized controlled trial

Autor: Karina Dalsgaard Sørensen, Pia Kirkegaard, Michael Vaeth, Jacob Fredsøe, Torben F. Ørntoft, Jan Koetsenruyter, Peter Vedsted, Adrian Edwards, Flemming Bro

Publikováno v: PLoS Medicine
PLoS Medicine, Vol 17, Iss 2, p e1003033 (2020)
Fredsøe, J, Koetsenruijter, J, Vedsted, P, Kirkegaard, P, Væth, M, Edwards, A, Ørntoft, T F, Sørensen, K D & Bro, F 2020, ' The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care : A cluster randomized controlled trial ', PLOS Medicine, vol. 17, no. 2, pp. e1003033 . https://doi.org/10.1371/journal.pmed.1003033

Background Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1f4b6a97280120dfc9cc4a4e6c47bb9
https://orca.cardiff.ac.uk/id/eprint/128812/8/journal.pmed.1003033.pdf